Author

E. Curry

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:statistical model· 3 Research Focus:chromatin & epigenetic regulation· 2 Assay:DNA methylation· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Assay:ChIP-seq· 1 Approach:deep learning· 1

Frequent Co-Authors

R. Brown· 2 shared A. Brown· 1 shared C. S. Wilhelm-Benartzi· 1 shared E. Loomis· 1 shared I. Eringyte· 1 shared I. Garner· 1 shared J. B. Rafferty· 1 shared J. Gallon· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

R. Brown

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Expanding the RNA polymerase biocatalyst solution space for mRNA manufacture

E. Curry, S. E. Sedelnikova, J. B. Rafferty, M. Hulley, A. Brown

This paper expands the RNA polymerase biocatalyst solution space for mRNA manufacture by identifying and validating eight novel RNAPs and their promoters through a high-throughput screening platform.

Biotechnology Journal · Jun 21, 2024Peer-reviewedBioengineering

Chromatin accessibility changes at intergenic regions associates with ovarian cancer drug resistance

J. Gallon, E. Loomis, E. Curry, N. Martin, L. Brody, I. Garner, R. Brown, J. M. Flanagan

The paper examines chromatin accessibility changes in ovarian cancer cell lines resistant to platinum-based chemotherapy, finding intergenic region alterations linked to drug resistance and Pt-adduct distribution.

bioRxiv · Feb 24, 2021Cancer Biology

Amplification of genomic regions harbouring genes with dose-limiting effects provides selection pressure for acquiring aberrant epigenetic silencing in ovarian cancer

N. Bonito, I. Eringyte, N. Masrour, C. S. Wilhelm-Benartzi, R. Brown, E. Curry

The paper shows that genomic copy number gains in ovarian cancer are associated with promoter methylation, which suppresses gene expression, and demonstrates this through functional experiments.

bioRxiv · May 7, 2019 · PreprintCancer Biology